Jefferies Group Increases BioMarin Pharmaceutical Price Target to $86.00 (BMRN)
Equities researchers at Jefferies Group upped their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $72.00 to $86.00 in a research report issued on Wednesday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target suggests a potential upside of 10.98% from the stock’s previous close.
BioMarin Pharmaceutical (NYSE:BMRN) traded up 2.02% on Wednesday, hitting $77.492. The stock had a trading volume of 3,191,145 shares. BioMarin Pharmaceutical has a one year low of $36.28 and a one year high of $78.83. The stock has a 50-day moving average of $67.2 and a 200-day moving average of $63.36. The company’s market cap is $10.857 billion.
A number of other analysts have also recently weighed in on BMRN. Analysts at Goldman Sachs Group Inc. raised their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $76.00 to $85.00 in a research note to investors on Wednesday. Analysts at Cowen and Company raised their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $79.00 to $85.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock.
One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $84.20.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.